Radical cystectomy (RC) after neoadjuvant chemotherapy (NAC) is the gold standard for management of muscle-invasive bladder cancer (MIBC). Patients without residual tumor at the time of extirpative surgery (ypT0) have excellent prognosis. Distant metastases in this population are rare. We present a unique case of a patient with ypT0N0 urothelial carcinoma (UC) with rapid development of metastasis to the brain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488483 | PMC |
| http://dx.doi.org/10.1016/j.eucr.2021.101838 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma.
BMC Cancer
January 2025
Department of Minimally Invasive Esophageal Surgery, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Background: In this study, we retrospectively examined the prognostic significance of the pathological status of esophageal squamous cell carcinoma (ESCC) patients following neoadjuvant chemoradiotherapy (NCRT) and surgery.
Methods: Data of patients with cT2-4aN0-3 stage ESCC who underwent NCRT and esophagectomy during 2014-2022 were reviewed retrospectively. Survival differences were compared according to revised TN (rTN) stage (ypT0N0, ypT + N0, ypT0N+, and ypT + N+) using univariate and Cox regression analyses.
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study.
Front Immunol
January 2025
Department of Thoracic Oncological Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Background: The role of immunotherapy in the adjuvant setting seems promising in recent years. As per the findings of the CheckMate 577 trial, patients with esophageal cancer (EC) who had neoadjuvant chemoradiation with residual pathologic disease should be considered adjuvant immunotherapy (AIT). However, it is unknown if individuals with esophageal squamous cell carcinoma (ESCC) who have received neoadjuvant immunochemotherapy (NICT) followed by radical surgery also require AIT.
View Article and Find Full Text PDFCharacterizing Patients with ypT0N1 Gastric Adenocarcinoma Within the AJCC Staging System.
Ann Surg Oncol
December 2024
Division of Gastrointestinal Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Introduction: The standard of care for gastric cancer in the United States involves perioperative chemotherapy. While most post-therapy pathologic staging results are concordant (i.e.
View Article and Find Full Text PDFPhase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma.
Cancer Sci
December 2024
Department of General Surgery, Air Force Medical University Tangdu Hospital, Xi'an, China.
Immune checkpoint inhibitors combined with chemotherapy have shown promising efficacy in treating gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the neoadjuvant setting. This phase II trial (NCT05715632) aimed to investigate the efficacy and safety of perioperative camrelizumab plus XELOX in patients with locally advanced G/GEJ adenocarcinoma. Treatment-naive patients with cT3-4aN1-3 M0 resectable locally advanced G/GEJ adenocarcinoma were recruited to receive camrelizumab (200 mg, intravenously) on Day 1 combined with XELOX (oxaliplatin at 130 mg/m on Day 1 and capecitabine at 1000 mg/m on Days 1-14) every 3 weeks for four cycles, followed by surgery and adjuvant camrelizumab combined with XELOX every 3 weeks for four cycles.
View Article and Find Full Text PDFNeoadjuvant camrelizumab followed by concurrent camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, phase II study.
J Thorac Dis
August 2024
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Article Synopsis
- - Neoadjuvant therapy combining camrelizumab and chemotherapy shows promise for treating locally advanced esophageal squamous cell carcinoma (ESCC), but the best way to use it alongside chemotherapy is still unclear.
- - In a study with 55 patients, the treatment led to a major pathological response rate of 77.1%, and almost all patients had successful surgeries with significant rates of tumor downstaging.
- - The results indicated a 2-year disease-free survival (DFS) rate of 68.9% and an overall survival (OS) rate of 74.7%, while serious treatment-related side effects occurred in 12.7% of patients, suggesting the therapy was effective and generally safe.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!